Published in J Infect Dis on November 01, 1990
Correlates of protection induced by vaccination. Clin Vaccine Immunol (2010) 5.21
A Blueprint for HIV Vaccine Discovery. Cell Host Microbe (2012) 3.27
Measles seropositivity in HIV-infected Kenyan children on antiretroviral therapy. Pediatr Infect Dis J (2014) 2.48
Measles control in developing and developed countries: the case for a two-dose policy. Bull World Health Organ (1993) 1.98
Immunogenicity, immunologic memory, and safety following measles revaccination in HIV-infected children receiving highly active antiretroviral therapy. J Infect Dis (2012) 1.98
Waning of maternal antibodies against measles, mumps, rubella, and varicella in communities with contrasting vaccination coverage. J Infect Dis (2013) 1.91
Interpretation of serological surveillance data for measles using mathematical models: implications for vaccine strategy. Epidemiol Infect (1995) 1.89
Baculovirus expression of the nucleoprotein gene of measles virus and utility of the recombinant protein in diagnostic enzyme immunoassays. J Clin Microbiol (1992) 1.87
Comparison of commercial enzyme immunoassay kits with plaque reduction neutralization test for detection of measles virus antibody. J Clin Microbiol (1995) 1.84
Timing of HAART defines the integrity of memory B cells and the longevity of humoral responses in HIV-1 vertically-infected children. Proc Natl Acad Sci U S A (2009) 1.84
Successful vaccine-induced seroconversion by single-dose immunization in the presence of measles virus-specific maternal antibodies. J Virol (2000) 1.74
Chikungunya virus and prospects for a vaccine. Expert Rev Vaccines (2012) 1.69
Immunology of gut mucosal vaccines. Immunol Rev (2011) 1.59
Contributions of humoral and cellular immunity to vaccine-induced protection in humans. Virology (2011) 1.53
High antibody titer against apical membrane antigen-1 is required to protect against malaria in the Aotus model. PLoS One (2009) 1.48
A threshold method for immunological correlates of protection. BMC Med Res Methodol (2013) 1.41
A recombinant measles virus expressing hepatitis B virus surface antigen induces humoral immune responses in genetically modified mice. J Virol (1999) 1.33
Neutralizing antibodies from the sera of human immunodeficiency virus type 1-infected individuals bind to monomeric gp120 and oligomeric gp140. J Virol (1998) 1.27
Associations between cytokine/cytokine receptor single nucleotide polymorphisms and humoral immunity to measles, mumps and rubella in a Somali population. Tissue Antigens (2008) 1.26
Development of a novel efficient fluorescence-based plaque reduction microneutralization assay for measles virus immunity. Clin Vaccine Immunol (2008) 1.21
A large observational study to concurrently assess persistence of measles specific B-cell and T-cell immunity in individuals following two doses of MMR vaccine. Vaccine (2011) 1.18
HIV-1 infection in Zambian children impairs the development and avidity maturation of measles virus-specific immunoglobulin G after vaccination and infection. J Infect Dis (2009) 1.17
Modulation of disease, T cell responses, and measles virus clearance in monkeys vaccinated with H-encoding alphavirus replicon particles. Proc Natl Acad Sci U S A (2005) 1.16
Role of CD8(+) lymphocytes in control and clearance of measles virus infection of rhesus monkeys. J Virol (2003) 1.15
Prolonged persistence of measles virus RNA is characteristic of primary infection dynamics. Proc Natl Acad Sci U S A (2012) 1.08
Correlations among measles virus-specific antibody, lymphoproliferation and Th1/Th2 cytokine responses following measles-mumps-rubella-II (MMR-II) vaccination. Clin Exp Immunol (2005) 1.07
Relative contributions of measles virus hemagglutinin- and fusion protein-specific serum antibodies to virus neutralization. J Virol (2005) 1.05
Consistency of HLA associations between two independent measles vaccine cohorts: a replication study. Vaccine (2012) 1.03
Seroprevalence of antibodies to measles, mumps, and rubella among Thai population: evaluation of measles/MMR immunization programme. J Health Popul Nutr (2009) 1.03
Biological feasibility of measles eradication. J Infect Dis (2011) 1.01
A chimeric alphavirus replicon particle vaccine expressing the hemagglutinin and fusion proteins protects juvenile and infant rhesus macaques from measles. J Virol (2010) 0.99
Human HLA class I- and HLA class II-restricted cloned cytotoxic T lymphocytes identify a cluster of epitopes on the measles virus fusion protein. J Virol (1993) 0.99
Antigen dose and humoral immune response correspond with protection for inactivated infectious pancreatic necrosis virus vaccines in Atlantic salmon (Salmo salar L). Vet Res (2013) 0.98
Demonstration of anti-tumor activity of oncolytic measles virus strains in a malignant pleural effusion breast cancer model. Breast Cancer Res Treat (2009) 0.98
Variability in immune response to pathogens: using measles vaccine to probe immunogenetic determinants of response. Am J Hum Genet (1998) 0.97
Safety and immunogenicity of early measles vaccination in children born to HIV-infected mothers in the United States: results of Pediatric AIDS Clinical Trials Group (PACTG) protocol 225. J Infect Dis (2011) 0.97
Development of replication-competent viral vectors for HIV vaccine delivery. Curr Opin HIV AIDS (2013) 0.96
Humoral and cellular immune responses to measles and tetanus: the importance of elapsed time since last exposure and the nature of the antigen. J Clin Immunol (2010) 0.96
A study of maternally derived measles antibody in infants born to naturally infected and vaccinated women. Epidemiol Infect (1996) 0.94
Measles virus-specific CD4 T-cell activity does not correlate with protection against lung infection or viral clearance. J Virol (2007) 0.94
Identification of primary and secondary measles vaccine failures by measurement of immunoglobulin G avidity in measles cases during the 1997 São Paulo epidemic. Clin Diagn Lab Immunol (2004) 0.93
Standardization of measles, mumps and rubella assays to enable comparisons of seroprevalence data across 21 European countries and Australia. Epidemiol Infect (2007) 0.93
Measles vaccine efficacy during an outbreak in a highly vaccinated population: incremental increase in protection with age at vaccination up to 18 months. Epidemiol Infect (1995) 0.93
Kinetics of decline of maternal measles virus-neutralizing antibodies in sera of infants in France in 2006. Clin Vaccine Immunol (2008) 0.92
Changes in measles serostatus among HIV-infected Zambian children initiating antiretroviral therapy before and after the 2010 measles outbreak and supplemental immunization activities. J Infect Dis (2013) 0.90
Immunosorbent assay based on recombinant hemagglutinin protein produced in a high-efficiency mammalian expression system for surveillance of measles immunity. J Clin Microbiol (1998) 0.90
Cross-sectional surveys of measles antibodies in the Jiangsu Province of China from 2008 to 2010: the effect of high coverage with two doses of measles vaccine among children. PLoS One (2013) 0.90
Successful boosting of a DNA measles immunization with an oral plant-derived measles virus vaccine. J Virol (2002) 0.89
Use of Vaxfectin adjuvant with DNA vaccine encoding the measles virus hemagglutinin and fusion proteins protects juvenile and infant rhesus macaques against measles virus. Clin Vaccine Immunol (2008) 0.89
Immune containment and consequences of measles virus infection in healthy and immunocompromised individuals. Clin Vaccine Immunol (2006) 0.87
Dose-dependent protection against or exacerbation of disease by a polylactide glycolide microparticle-adsorbed, alphavirus-based measles virus DNA vaccine in rhesus macaques. Clin Vaccine Immunol (2008) 0.86
Measles virus-specific antibody levels in individuals in Argentina who received a one-dose vaccine. J Clin Microbiol (2006) 0.86
Characterization of immune responses induced by intramuscular vaccination with DNA vaccines encoding measles virus hemagglutinin and/or fusion proteins. J Virol (2005) 0.85
Genetic factors influence serological measures of common infections. Hum Hered (2011) 0.85
Acute measles encephalitis in partially vaccinated adults. PLoS One (2013) 0.84
Vaccine-mediated immunity against dengue and the potential for long-term protection against disease. Front Immunol (2014) 0.83
Comparison of the immune responses induced by chimeric alphavirus-vectored and formalin-inactivated alum-precipitated measles vaccines in mice. PLoS One (2010) 0.83
A microneedle patch containing measles vaccine is immunogenic in non-human primates. Vaccine (2015) 0.83
Microparasite population dynamics and continuous immunity. Proc Biol Sci (1998) 0.82
Twice vaccinated recipients are better protected against epidemic measles than are single dose recipients of measles containing vaccine. J Epidemiol Community Health (1999) 0.82
A chimeric human-bovine parainfluenza virus type 3 expressing measles virus hemagglutinin is attenuated for replication but is still immunogenic in rhesus monkeys. J Virol (2001) 0.82
Measles immunity and response to revaccination among secondary school children in Cumbria. Epidemiol Infect (1996) 0.81
Sang Froid in a time of trouble: is a vaccine against HIV possible? J Int AIDS Soc (2009) 0.81
Epidemiology of measles in Taiwan: dynamics of transmission and timeliness of reporting during an epidemic in 1988-9. Epidemiol Infect (1995) 0.81
A global perspective of vaccination of healthcare personnel against measles: systematic review. Vaccine (2013) 0.81
Neutralization of measles virus infectivity and antibody-dependent cell-mediated cytotoxicity activity against an Epstein-Barr virus-infected cell line by intravenous immunoglobulin G [corrected]. Clin Diagn Lab Immunol (2003) 0.80
Lower transplacental antibody transport for measles, mumps, rubella and varicella zoster in very preterm infants. PLoS One (2014) 0.80
Neutralization capacity of measles virus H protein specific IgG determines the balance between antibody-enhanced infectivity and protection in microglial cells. Virus Res (2012) 0.80
Vaccine-induced measles virus-specific T cells do not prevent infection or disease but facilitate subsequent clearance of viral RNA. MBio (2014) 0.80
Measles humoral and cell-mediated immunity in children aged 5-10 years after primary measles immunization administered at 6 or 9 months of age. J Infect Dis (2013) 0.80
Antibody levels to tetanus, diphtheria, measles and varicella in patients with primary immunodeficiency undergoing intravenous immunoglobulin therapy: a prospective study. BMC Immunol (2014) 0.79
Long-term safety and serologic response to measles, mumps, and rubella vaccination in HIV-1 infected adults. Vaccine (2011) 0.79
Priming T-cell responses with recombinant measles vaccine vector in a heterologous prime-boost setting in non-human primates. Vaccine (2012) 0.79
Mucosal IgA responses in healthy adult volunteers following intranasal spray delivery of a live attenuated measles vaccine. Clin Vaccine Immunol (2011) 0.79
Noninterference of Rotavirus Vaccine With Measles-Rubella Vaccine at 9 Months of Age and Improvements in Antirotavirus Immunity: A Randomized Trial. J Infect Dis (2016) 0.79
Immunity to Measles, Mumps, and Rubella in US Children With Perinatal HIV Infection or Perinatal HIV Exposure Without Infection. Clin Infect Dis (2015) 0.79
Vaxfectin adjuvant improves antibody responses of juvenile rhesus macaques to a DNA vaccine encoding the measles virus hemagglutinin and fusion proteins. J Virol (2013) 0.79
High Concentrations of Measles Neutralizing Antibodies and High-Avidity Measles IgG Accurately Identify Measles Reinfection Cases. Clin Vaccine Immunol (2016) 0.79
Modelling the effect of a booster vaccination on disease epidemiology. J Math Biol (2005) 0.78
Increasing the time of exposure to aerosol measles vaccine elicits an immune response equivalent to that seen in 9-month-old Mexican children given the same dose subcutaneously. J Infect Dis (2011) 0.77
Measles virus expressed Helicobacter pylori neutrophil-activating protein significantly enhances the immunogenicity of poor immunogens. Vaccine (2013) 0.77
Susceptibility to Measles Among Perinatally HIV-Infected Adolescents and Young Adults. J Pediatric Infect Dis Soc (2013) 0.77
Transplacental transfer of macromolecules: proving the efficiency of placental transfer of maternal measles antibodies in mother: infant pairs. Ann Med Health Sci Res (2014) 0.77
Seroprevalence of measles, mumps and rubella among young adults, after 20 years of universal 2-dose MMR vaccination in Israel. Hum Vaccin Immunother (2015) 0.77
Impact of acute malaria on pre-existing antibodies to viral and vaccine antigens in mice and humans. PLoS One (2015) 0.77
Evaluation of a two-dose measles, mumps, and rubella vaccination schedule in a cohort of college athletes. Public Health Rep (1993) 0.76
Complex immune correlates of protection in HIV-1 vaccine efficacy trials. Immunol Rev (2017) 0.76
HPV vaccines: Translating immunogenicity into efficacy. Hum Vaccin Immunother (2015) 0.76
Profiling of measles-specific humoral immunity in individuals following two doses of MMR vaccine using proteome microarrays. Viruses (2015) 0.76
Chikungunya vaccines in development. Hum Vaccin Immunother (2016) 0.76
Murine Monoclonal Antibodies for Antigenic Discrimination of HIV-1 Envelope Proteins. Viral Immunol (2015) 0.75
Performance Evaluation of the VIDAS(®) Measles IgG Assay and Its Diagnostic Value for Measuring IgG Antibody Avidity in Measles Virus Infection. Viruses (2016) 0.75
Measles immunometrics. Proc Natl Acad Sci U S A (2012) 0.75
Effect of multivitamin supplementation on measles vaccine response among HIV-exposed uninfected Tanzanian infants. Clin Vaccine Immunol (2013) 0.75
Dot immunobinding assay for simultaneous detection of specific immunoglobulin G antibodies to measles virus, mumps virus, and rubella virus. J Clin Microbiol (1993) 0.75
The Immune Response in Measles: Virus Control, Clearance and Protective Immunity. Viruses (2016) 0.75
T cell anergy and activation are associated with suboptimal humoral responses to measles revaccination in HIV-infected children on anti-retroviral therapy in Nairobi, Kenya. Clin Exp Immunol (2015) 0.75
Pain and its treatment in outpatients with metastatic cancer. N Engl J Med (1994) 9.54
Rubella hemagglutinin prepared with alkaline extraction of virus grown in suspension culture of BHK-21 cells. Proc Soc Exp Biol Med (1967) 5.61
Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012). AIDS (2001) 5.31
Field evaluation of vaccine efficacy. Bull World Health Organ (1985) 4.95
Prior herpes simplex virus type 2 infection as a risk factor for HIV infection. JAMA (1988) 3.89
Rational strategy for rubella vaccination. Lancet (1983) 3.61
Isolation and identification of Haemophilus ducreyi in a clinical study. J Clin Microbiol (1980) 3.40
Measles vaccine efficacy in children previously vaccinated at 12 months of age. Pediatrics (1978) 2.98
Perinatal transmission of human immunodeficiency virus type 1 by pregnant women with RNA virus loads <1000 copies/ml. J Infect Dis (2001) 2.95
Rubella hemagglutinin prepared in serum free suspension culture of BHK-21 cells. Ann Med Exp Biol Fenn (1967) 2.89
A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology (2006) 2.75
Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type 1. Pediatric AIDS Clinical Trials Group 382 Team. N Engl J Med (1999) 2.67
Persistence of maternal antibody in infants beyond 12 months: mechanism of measles vaccine failure. J Pediatr (1977) 2.66
Benefits, risks and costs of immunization for measles, mumps and rubella. Am J Public Health (1985) 2.58
Epidemiology of poliomyelitis in the United States one decade after the last reported case of indigenous wild virus-associated disease. Clin Infect Dis (1992) 2.55
Identification of the K103N resistance mutation in Ugandan women receiving nevirapine to prevent HIV-1 vertical transmission. AIDS (2000) 2.49
The microbiological flora of penile ulcerations. J Infect Dis (1978) 2.43
Transfer function analysis of the circulation: unique insights into cardiovascular regulation. Am J Physiol (1991) 2.42
Patterns of transmission in measles outbreaks in the United States, 1985-1986. N Engl J Med (1989) 2.41
Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea in children: a randomized double-blind placebo-controlled trial. Aliment Pharmacol Ther (2005) 2.36
Vaccine-associated paralytic poliomyelitis. United States: 1973 through 1984. JAMA (1987) 2.28
Indirect hemagglutination test for detection of antibodies to Cytomegalovirus. Appl Microbiol (1971) 2.28
Recovery from a viral respiratory infection. II. Passive transfer of immune spleen cells to mice with influenza pneumonia. J Immunol (1981) 2.19
A persistent outbreak of measles despite appropriate prevention and control measures. Am J Epidemiol (1987) 2.13
Congenital rubella syndrome in the United States, 1970-1985. On the verge of elimination. Am J Epidemiol (1989) 2.12
Continuing measles transmission in students despite school-based outbreak control program. Am J Epidemiol (1985) 2.09
Additive efficacy of unoprostone isopropyl 0.12% (rescula) to latanoprost 0.005%. Am J Ophthalmol (2001) 2.06
Multidisciplinary approach to deep-seated lesions requiring radiologically-guided fine-needle aspiration. Diagn Cytopathol (1998) 2.04
Recovery from a viral respiratory infection. I. Influenza pneumonia in normal and T-deficient mice. J Immunol (1981) 2.04
Cytomegalovirus specific IgM and IgG response in humans studied by radioimmunoassay. J Immunol (1976) 2.03
Role of virus strain in conventional and enhanced measles plaque neutralization test. J Virol Methods (1981) 1.96
Risk factors for outbreaks of influenza in nursing homes. A case-control study. Am J Epidemiol (1986) 1.93
T wave alternans during exercise and atrial pacing in humans. J Cardiovasc Electrophysiol (1997) 1.92
From the Center for Disease control: current status of measles in the United States, 1973--1977. J Infect Dis (1978) 1.91
Progress in measles elimination. JAMA (1982) 1.87
Measles infection of human mononuclear cells. I. Acute infection of peripheral blood lymphocytes and monocytes. J Exp Med (1975) 1.86
Molecular subtyping of Treponema pallidum in an Arizona County with increasing syphilis morbidity: use of specimens from ulcers and blood. J Infect Dis (2001) 1.86
Successes and failures in measles control. J Infect Dis (1994) 1.84
Controlled clinical trial of prophylactic human-leukocyte interferon in renal transplantation. Effects on cytomegalovirus and herpes simplex virus infections. N Engl J Med (1979) 1.83
Immunization of six-month-old infants with different doses of Edmonston-Zagreb and Schwarz measles vaccines. N Engl J Med (1990) 1.82
Modulation of cardiac autonomic activity during and immediately after exercise. Am J Physiol (1989) 1.81
Cytomegalovirus pneumonia after human marrow transplantation. Ann Intern Med (1975) 1.80
Appropriate age for measles vaccination in the United States. Dev Biol Stand (1986) 1.80
Age-specific risks of varicella complications. Pediatrics (1981) 1.76
A cluster of patients with a chronic mononucleosis-like syndrome. Is Epstein-Barr virus the cause? JAMA (1987) 1.75
Epidemic giardiasis caused by a contaminated public water supply. Am J Public Health (1988) 1.72
The resurgence of measles in the United States, 1989-1990. Annu Rev Med (1992) 1.72
The case for global eradication of poliomyelitis. Bull World Health Organ (1987) 1.72
Health impact of measles vaccination in the United States. Pediatrics (1985) 1.71
Current status of mumps and mumps vaccine in the United States. Pediatrics (1978) 1.71
Method for typing antisera to Herpesvirus hominis by indirect hemagglutination inhibition. Appl Microbiol (1971) 1.70
How reliable is the morphological diagnosis of penile ulcerations? Sex Transm Dis (1978) 1.70
Measles outbreak in a vaccinated school population: epidemiology, chains of transmission and the role of vaccine failures. Am J Public Health (1987) 1.70
Duration of live measles vaccine-induced immunity. Pediatr Infect Dis J (1990) 1.70
Outbreak of paralytic poliomyelitis, Taiwan. Lancet (1984) 1.68
Evaluation of monoclonal antibody-based capture enzyme immunoassays for detection of specific antibodies to measles virus. J Clin Microbiol (1991) 1.68
Poliomyelitis outbreak in Israel in 1988: a report with two commentaries. Lancet (1990) 1.67
Power law behavior of RR-interval variability in healthy middle-aged persons, patients with recent acute myocardial infarction, and patients with heart transplants. Circulation (1996) 1.67
Biomarker evidence for a major preservation pathway of sedimentary organic carbon. Science (2006) 1.66
Spontaneous cytomegalovirus mononucleosis. Clinical and laboratory observations in nine cases. Ann Intern Med (1973) 1.65
Epidemiology of pertussis, Atlanta, 1977. J Pediatr (1981) 1.62
Surveillance for congenital cytomegalovirus disease: a report from the National Congenital Cytomegalovirus Disease Registry. Clin Infect Dis (1995) 1.60
Association of maternal drug use during pregnancy with maternal HIV culture positivity and perinatal HIV transmission. AIDS (1996) 1.59
Measles outbreak among unvaccinated preschool-aged children: opportunities missed by health care providers to administer measles vaccine. Pediatrics (1989) 1.57
Combined doppler and phased-array echocardiographic estimation of cardiac output. Circulation (1981) 1.57
Untreated 24-h intraocular pressures measured with Goldmann applanation tonometry vs nighttime supine pressures with Perkins applanation tonometry. Eye (Lond) (2009) 1.57
Experimental alveolar lipo-proteinosis following the inhalation of silica. J Pathol (1970) 1.56
A long-term follow-up study of patients with post-poliomyelitis neuromuscular symptoms. N Engl J Med (1986) 1.53
Rubella vaccination in the United States: a ten-year review. Epidemiol Rev (1980) 1.53
Reporting efficiency during a measles outbreak in New York City, 1991. Am J Public Health (1993) 1.53
An explosive point-source measles outbreak in a highly vaccinated population. Modes of transmission and risk factors for disease. Am J Epidemiol (1989) 1.53
Transfer of measles, mumps, and rubella antibodies from mother to infant. Its effect on measles, mumps, and rubella immunization. Am J Dis Child (1979) 1.51
Elimination of indigenous measles from the United States. Rev Infect Dis (1983) 1.50
Prevalence of measles antibodies in asymptomatic human immunodeficiency virus-infected adults. J Infect Dis (1991) 1.50
Fetal risk associated with rubella vaccine: an update. Rev Infect Dis (1985) 1.50
Rubella complement fixing antigen prepared by alkaline extraction of virus grown in suspension culture of BHK-211 cells. Proc Soc Exp Biol Med (1967) 1.49
The pancreas in recent-onset type 1 (insulin-dependent) diabetes mellitus: insulin content of islets, insulitis and associated changes in the exocrine acinar tissue. Diabetologia (1984) 1.48
Doctors who do not feel sober enough to drive should avoid helping in medical emergencies. BMJ (1998) 1.47
Inhibition of lymphocyte stimulation by measles virus. J Immunol (1975) 1.47
Collagen content of alveolar wall tissue in emphysematous and non-emphysematous lungs. Thorax (1994) 1.46
Can perinatal HIV infection be eliminated in the United States? JAMA (1999) 1.46
Pathogenesis of neurotropic arbovirus infections. Curr Top Microbiol Immunol (1968) 1.46
Causes of low preschool immunization coverage in the United States. Annu Rev Public Health (1992) 1.45